AR110038A1 - Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos - Google Patents

Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos

Info

Publication number
AR110038A1
AR110038A1 ARP170101409A ARP170101409A AR110038A1 AR 110038 A1 AR110038 A1 AR 110038A1 AR P170101409 A ARP170101409 A AR P170101409A AR P170101409 A ARP170101409 A AR P170101409A AR 110038 A1 AR110038 A1 AR 110038A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
egfr
methods
hydrogen
Prior art date
Application number
ARP170101409A
Other languages
English (en)
Inventor
Rakesh Kumar Sit
Joseph Robert Pinchman
Kevin Duane Bunker
Chad Daniel Hopkins
Sayee Gajanan Hegde
Deborah Helen Slee
Peter Qinhua Huang
Original Assignee
Kalyra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalyra Pharmaceuticals Inc filed Critical Kalyra Pharmaceuticals Inc
Publication of AR110038A1 publication Critical patent/AR110038A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
    • C07C13/36—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with a bicyclo ring system containing five carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms

Abstract

Reivindicación 1: Un compuesto inhibidor de EGFR, de fórmula (1) o una sal farmacéuticamente aceptable del mismo, caracterizado porque la fórmula (1) tiene la estructura mostrada a continuación, R¹ se selecciona entre hidrógeno, halógeno, hidroxi, ciano, un alquilo C₁₋₄ opcionalmente sustituido, un haloalquilo C₁₋₄ opcionalmente sustituido, un alcoxi C₁₋₄ opcionalmente sustituido y un haloalcoxi C₁₋₄ opcionalmente sustituido; R² es un heteroarilo de 6 a 15 miembros opcionalmente sustituido o un heterociclilo de 6 a 15 miembros opcionalmente sustituido, donde el heteroarilo y el heterociclilo, en forma independiente, contienen de 1 a 4 heteroátomos seleccionados entre N, O y S; R³ se selecciona entre hidrógeno, halógeno, un alquilo C₁₋₄ opcionalmente sustituido, un cicloalquilo C₃₋₈ opcionalmente sustituido, un arilo opcionalmente sustituido, un heteroarilo opcionalmente sustituido y un heterociclilo opcionalmente sustituido, considerando que, cuando está sustituido, R³ esta sustituido por uno o más sustituyentes seleccionados entre halógeno, ciano, un alquilo C₁₋₄ insustituido, un arilo opcionalmente sustituido, -C(O)R⁵A, -SO₂R⁵B, -NHC(O)R⁵C y -(CR⁶AR⁶B)ₙNR⁷AR⁷B; X¹ es O, S o NR⁴; R⁴ se selecciona entre hidrógeno, un alquilo C₁₋₄ opcionalmente sustituido, un haloalquilo C₁₋₄ opcionalmente sustituido y un cicloalquilo C₃₋₈ opcionalmente sustituido; R⁵A, R⁵B y R⁵C se seleccionan independientemente entre hidrógeno, un alquilo C₁₋₄ opcionalmente sustituido, un haloalquilo C₁₋₄ opcionalmente sustituido, un cicloalquilo C₃₋₈ opcionalmente sustituido, un arilo opcionalmente sustituido, un heteroarilo opcionalmente sustituido, y un heterociclilo opcionalmente sustituido; R⁶A y R⁶B se seleccionan independientemente entre hidrógeno, halógeno, un alquilo C₁₋₄ opcionalmente sustituido, un haloalquilo C₁₋₄ opcionalmente sustituido y un cicloalquilo C₃₋₈ opcionalmente sustituido; R⁷A y R⁷B se seleccionan independientemente entre hidrógeno, un alquilo C₁₋₄ opcionalmente sustituido, un haloalquilo C₁₋₄ opcionalmente sustituido y un cicloalquilo C₃₋₈ opcionalmente sustituido; A¹ es N o CR⁸; R⁸ se selecciona entre hidrógeno. halógeno, ciano, un alquilo C₁₋₄ opcionalmente sustituido, un haloalquilo C₁₋₄ opcionalmente sustituido y un cicloalquilo C₃₋₈ opcionalmente sustituido; m es 0 ó 1 y n es 0, 1, 2 ó 3, y con la condición de que R² este sustituido con biciclo[1,1,1]pentilo o R³ sea un biciclo[1,1,1]pentilo sustituido.
ARP170101409A 2016-05-26 2017-05-24 Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos AR110038A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662342141P 2016-05-26 2016-05-26

Publications (1)

Publication Number Publication Date
AR110038A1 true AR110038A1 (es) 2019-02-20

Family

ID=60411884

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101409A AR110038A1 (es) 2016-05-26 2017-05-24 Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos

Country Status (15)

Country Link
US (3) US10513509B2 (es)
EP (1) EP3464275A4 (es)
JP (1) JP7030066B2 (es)
KR (2) KR20220130249A (es)
CN (2) CN112624954A (es)
AR (1) AR110038A1 (es)
AU (2) AU2017269335B2 (es)
BR (1) BR112018074232A2 (es)
CA (1) CA3023176A1 (es)
IL (2) IL263081B (es)
MX (2) MX2018013413A (es)
RU (1) RU2751341C2 (es)
SG (2) SG10202102920QA (es)
TW (1) TWI752033B (es)
WO (1) WO2017205459A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3023176A1 (en) 2016-05-26 2017-11-30 Zeno Royalties & Milestones, LLC Egfr inhibitor compounds
CN108864079B (zh) * 2017-05-15 2021-04-09 深圳福沃药业有限公司 一种三嗪化合物及其药学上可接受的盐
AU2018329815B2 (en) 2017-09-11 2023-02-16 Recurium Ip Holdings, Llc Continuous flow processes for making bicyclic compounds
CN110041302B (zh) * 2019-03-01 2021-11-30 南方医科大学 2-氨基-4-取代吡啶衍生物及其合成方法和应用
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
CA3138648A1 (en) * 2019-05-22 2020-11-26 Shanghai Hansoh Biomedical Co., Ltd. Indole derivative-containing inhibitor, preparation method therefor and application thereof
US20220229072A1 (en) 2019-06-04 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021259316A1 (zh) * 2020-06-23 2021-12-30 深圳福沃药业有限公司 化合物的结晶形式
EP4330256A1 (en) * 2021-04-30 2024-03-06 Suzhou Puhe Biopharma Co., Ltd. Pyrimidinylaminobenzenes for lung cancer treatment

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1051350A (en) 1910-02-02 1913-01-21 Thomas Nogier Apparatus for the sterilization of liquids.
DE4124942A1 (de) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CA2148931A1 (en) 1993-10-01 1995-04-13 Jurg Zimmermann Pyrimidineamine derivatives and processes for the preparation thereof
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
DE60214198T2 (de) * 2001-07-03 2007-08-09 Vertex Pharmaceuticals Inc., Cambridge Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
US7396940B2 (en) 2003-10-23 2008-07-08 Hoffmann-La Roche Inc. Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid
US20080153869A1 (en) 2004-06-14 2008-06-26 Bressi Jerome C Kinase Inhibitors
CN101048407A (zh) 2004-09-03 2007-10-03 普莱希科公司 双环杂芳基pde4b抑制剂
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
RU2007136784A (ru) 2005-03-04 2009-04-10 Мерк энд Ко., Инк. (US) Конденсированные ароматические соединения, обладающие антидиабетической активностью
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
JP2009541318A (ja) 2006-06-22 2009-11-26 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
US8338458B2 (en) 2007-05-07 2012-12-25 Merck Sharp & Dohme Corp. Method of treatment using fused aromatic compounds having anti-diabetic activity
JP2010031249A (ja) 2008-06-23 2010-02-12 Sumitomo Chemical Co Ltd 組成物及び該組成物を用いてなる発光素子
RU2536584C2 (ru) * 2008-06-27 2014-12-27 Авила Терапьютикс, Инк. Гетероарильные соединения и их применение
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
AU2010292198A1 (en) 2009-09-09 2012-04-05 Celgene Avilomics Research, Inc. PI3 kinase inhibitors and uses thereof
KR101116234B1 (ko) 2009-10-29 2014-03-06 (주)퓨쳐켐 (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
UY33539A (es) 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
WO2012050393A2 (ko) 2010-10-14 2012-04-19 제이더블유중외제약 주식회사 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도
CN103476768B (zh) 2011-03-16 2015-07-08 弗·哈夫曼-拉罗切有限公司 6,5-杂环炔丙醇化合物及其用途
US20140303163A1 (en) 2011-03-24 2014-10-09 Ying Luo Use of kinase inhibitors in preventing and treating inflammatory disorder
AU2012288626C1 (en) * 2011-07-27 2015-09-17 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as EGFR modulators useful for treating cancer
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
US20150087628A1 (en) 2012-04-10 2015-03-26 The Regents Of The University Of California Compositions and methods for treating cancer
CN103508961B (zh) 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
RS58192B1 (sr) 2012-11-21 2019-03-29 Janssen Biotech Inc Bispecifična egfr/c-met antitela
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
RU2634694C2 (ru) 2013-04-29 2017-11-03 Чонг Кун Данг Фармасьютикал Корп. Новые соединения для селективных ингибиторов гистондеацетилазы и фармацевтическая композиция, включающая такие соединения
US20180057603A1 (en) 2013-08-09 2018-03-01 The Trustees Of The University Of Pennsylvania Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
JP6524094B2 (ja) 2013-08-30 2019-06-05 ピーティーシー セラピューティクス， インコーポレイテッド 置換ピリミジンＢｍｉ−１阻害剤
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy
AU2014331118B2 (en) 2013-10-01 2019-07-25 Medimmune Limited Methods of treating and diagnosing alpha-V-beta-6 overexpressing cancer
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
CN104761544B (zh) 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
WO2015112705A2 (en) 2014-01-24 2015-07-30 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
WO2015127234A1 (en) 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN104876914B (zh) 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
CN104892585B (zh) 2014-03-06 2018-07-03 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
HUE042753T2 (hu) * 2014-04-04 2019-07-29 Syros Pharmaceuticals Inc A ciklin-dependens kináz 7 enzim (CDK 7) inhibitorai
PL3125885T3 (pl) 2014-04-04 2021-12-06 Astrazeneca Ab Kombinacja inhibitora EGFR i inhibitora MEK do zastosowania w leczeniu nowotworu złośliwego z mutacją NRAS
WO2015175965A1 (en) 2014-05-15 2015-11-19 The Research Foundation For Suny Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof
CN106660993B (zh) 2014-06-12 2020-09-11 上海复尚慧创医药研究有限公司 一类激酶抑制剂
CA2949793C (en) * 2014-06-19 2024-02-27 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN105254615B (zh) 2014-07-11 2017-02-22 杭州华东医药集团新药研究院有限公司 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途
ES2774428T3 (es) 2014-07-11 2020-07-21 Genmab As Anticuerpos que se unen a AXL
CN105315285B (zh) 2014-07-25 2017-12-08 上海海雁医药科技有限公司 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
CN104140418B (zh) 2014-08-15 2016-08-24 常州润诺生物科技有限公司 2-(2，4，5-取代苯胺)嘧啶衍生物及其用途
EP3180029A1 (en) 2014-08-15 2017-06-21 Boehringer Ingelheim International GmbH Afatinib pharmaceutical kit for cancer treatment
WO2016029839A1 (zh) 2014-08-25 2016-03-03 四川海思科制药有限公司 一种（取代的苯基）（取代的嘧啶）胺基衍生物及其制备方法和药物用途
JPWO2016032003A1 (ja) 2014-08-30 2017-07-13 国立大学法人金沢大学 肺癌患者用治療剤及び肺癌患者治療の有効性の予測検査方法
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016038609A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
WO2016040622A1 (en) 2014-09-11 2016-03-17 Bulldog Pharmaceuticals, Inc. Uses of anti-her3 antibodies for treating cancer
ES2843829T3 (es) 2014-09-26 2021-07-20 Hi Stem Ggmbh Im Deutschen Krebsforschungszentrum Dkfz Nuevos métodos para la subtipificación y el tratamiento del cáncer
CN105461695B (zh) 2014-09-29 2018-03-27 齐鲁制药有限公司 嘧啶或三嗪衍生物及其制备方法和用途
CN105237515B (zh) 2014-10-10 2018-06-05 益方生物科技（上海）有限公司 氘代嘧啶类化合物、其制备方法、药物组合物和用途
BR112017006713B1 (pt) * 2014-10-11 2023-11-21 Shanghai Hansoh Biomedical Co., Ltd. Inibidores de egfr, seus usos e seu processo de preparação, e composição farmacêutica
EP3604294B1 (en) * 2014-10-13 2021-05-05 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
US10308648B2 (en) 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016090174A1 (en) 2014-12-03 2016-06-09 Auckland Uniservices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
MX2017007664A (es) 2014-12-11 2018-01-23 Beta Pharma Inc Derivados de 2-anilinopirimidina sustituida como moduladores de egfr.
US20180193274A1 (en) 2014-12-24 2018-07-12 Principia Biopharma Inc. Compositions for ileo-jejunal drug delivery
WO2016112302A1 (en) 2015-01-09 2016-07-14 Metastat, Inc. Method of predicting sensitivity of tumor cell growth to combination therapy of fgfr inhibitor
WO2016112272A1 (en) 2015-01-09 2016-07-14 Metastat, Inc. Method of use for inhibitors of epidermal growth factor receptor variant iii
AU2016216253B2 (en) 2015-02-04 2019-11-21 Beyondbio Inc. Heterocyclic compound and pharmaceutical composition comprising same
ES2808781T3 (es) 2015-02-05 2021-03-01 Tyrnovo Ltd Combinaciones de moduladores duales de IRS/STAT3 y agentes anticancerígenos para el tratamiento del cáncer
CN104961731A (zh) 2015-02-05 2015-10-07 苏州晶云药物科技有限公司 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法
CN105985323A (zh) 2015-02-15 2016-10-05 宁波文达医药科技有限公司 新型表皮生长因子受体抑制剂及其应用
WO2016141324A2 (en) 2015-03-05 2016-09-09 Trovagene, Inc. Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluids
CN106138061B (zh) 2015-04-03 2019-06-04 中国人民解放军第三军医大学第三附属医院 预防或减弱肺纤维化的复合物及其制剂和用途
CN106138020A (zh) 2015-04-03 2016-11-23 中国人民解放军第三军医大学第三附属医院 双胍类药物在制备预防或减弱肺纤维化的药物中的应用
WO2016164217A1 (en) 2015-04-09 2016-10-13 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
CN104844580B (zh) 2015-04-17 2017-10-20 中国药科大学 嘧啶类化合物、其制备方法及医药用途
US20180147279A1 (en) 2015-04-23 2018-05-31 Medimmune Limited Combination therapy for non-small cell lung cancer positive for egfr mutation
CN104817541B (zh) 2015-05-11 2017-06-16 苏州东南药业股份有限公司 一种抗肿瘤药物的合成方法
JP6949726B2 (ja) 2015-05-15 2021-10-13 ノバルティス アーゲー Ｅｇｆｒ変異癌を治療する方法
MA42133A (fr) 2015-05-21 2021-06-02 Chemocentryx Inc Modulateurs du ccr2
WO2016191471A1 (en) 2015-05-27 2016-12-01 Metastat, Inc. Method of use for inhibitors of epidermal growth factor receptor variants ii, iii and vi
CN108289922B (zh) 2015-06-03 2022-02-08 友杏生技医药股份有限公司 用于治疗非小细胞肺癌的治疗方法和组合物
US20160355503A1 (en) 2015-06-04 2016-12-08 Cleave Biosciences, Inc. NITROGEN HEXACYCLE COMPOUNDS AS INHIBITORS OF p97 COMPLEX
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN104910049B (zh) 2015-06-16 2016-06-29 苏州明锐医药科技有限公司 Azd9291中间体及其制备方法
EP3319993B1 (en) 2015-07-10 2020-01-15 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
WO2017011907A1 (en) 2015-07-17 2017-01-26 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2
EP3325469A4 (en) 2015-07-20 2019-01-23 Dana Farber Cancer Institute, Inc. NOVEL PYRIMIDINES USEFUL AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
EP3120851A1 (en) 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
EP3327014A4 (en) 2015-07-24 2019-01-02 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
CN105001208A (zh) 2015-08-06 2015-10-28 南京雷科星生物技术有限公司 一种表皮生长因子受体egfr抑制剂及其制备方法与用途
US10980765B2 (en) 2015-08-14 2021-04-20 Board Of Supervisors Of Louisiana State University Isothiocyanatostilbenes as a novel method and product for treating cancer
CN105153122B (zh) 2015-08-27 2018-07-20 上海圣考医药科技有限公司 [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用
CN110483485A (zh) 2015-09-02 2019-11-22 益方生物科技（上海）有限公司 嘧啶类化合物、其制备方法和医药用途
CN105126125A (zh) 2015-09-12 2015-12-09 复旦大学 一种氧化锌-钆-药物复合纳米粒子及其制备方法和应用
CA2995430C (en) 2015-09-25 2023-07-11 Dizal (Jiangsu) Pharmaceutical Co., Limited Compounds and methods for inhibiting jak
AU2016343517B2 (en) 2015-10-19 2020-04-30 Sunshine Lake Pharma Co., Ltd. A salt of EGFR inhibitor, crystalline form and uses thereof
US20170115275A1 (en) 2015-10-23 2017-04-27 Arizona Board Of Regents On Behalf Of Arizona State University Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development
US10093668B2 (en) 2015-10-28 2018-10-09 Northwestern University Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2)
US9938264B2 (en) 2015-11-02 2018-04-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
CN106674202A (zh) 2015-11-05 2017-05-17 惠州信立泰药业有限公司 化合物a的二甲磺酸盐及其晶型和含有该盐的药物组合物
CN106699736A (zh) 2015-11-17 2017-05-24 惠州信立泰药业有限公司 化合物A甲磺酸盐的晶型γ和含有该晶型的药物组合物
CN105294717B (zh) 2015-11-18 2017-12-22 乳源瑶族自治县大众药品贸易有限公司 一种egfr抑制剂的盐、晶型及其用途
CN105461729B (zh) 2015-11-18 2017-12-05 乳源瑶族自治县大众药品贸易有限公司 一种egfr抑制剂的盐、晶型及其用途
RU2603960C1 (ru) 2015-11-19 2016-12-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Дихлорацетат n1,n2-дизамещенного n4-[4-(1-метил-1н-индол-3-ил)-пиримидин-2-ил]-5-метоксибензол-1,2,4-триамина в качестве модулятора egfr для лечения рака
RU2606949C9 (ru) 2015-11-19 2018-03-14 ЗАО "Р-Фарм" Замещенные N-{ 3-[4-(1-метил-1Н-индол-3-ил)пиримидин-2-иламино]-4-метоксифенил} -амиды в качестве модуляторов EGFR, предназначенные для лечения рака
CN105348267A (zh) 2015-12-01 2016-02-24 中山奕安泰医药科技有限公司 合成azd9291中间体的方法
CA3007110A1 (en) 2015-12-03 2017-06-08 Shanghai Aeon Biotech Co., Ltd. Heterocycle compounds and uses thereof
WO2017096095A1 (en) 2015-12-03 2017-06-08 Shanghai Aeon Biotech Co., Ltd. Thieno-pyrimidine derivatives and uses thereof
EP3387017A1 (en) 2015-12-11 2018-10-17 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
TWI623316B (zh) 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
CN105601620A (zh) 2015-12-25 2016-05-25 北京康立生医药技术开发有限公司 一种甲磺酸迈瑞替尼的制备方法
EP3394047B1 (en) 2015-12-27 2019-12-11 Neuform Pharmaceuticals, Inc. Deuterated compounds for treating cancer and compositions and methods thereof
CN106928150B (zh) 2015-12-31 2020-07-31 恩瑞生物医药科技（上海）有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
WO2017120429A1 (en) 2016-01-07 2017-07-13 CS Pharmasciences, Inc. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
CN108601746A (zh) 2016-01-08 2018-09-28 加利福尼亚大学董事会 用于运载物递送的具有脂质双层包衣的中孔二氧化硅纳米颗粒
CA3010848A1 (en) 2016-01-08 2017-07-13 Euclises Pharmaceuticals, Inc. Combination of a chromene compound and a second active agent
CN105646454B (zh) 2016-01-19 2018-05-08 浙江大学 含异羟肟酸片段的2-芳胺基嘧啶类衍生物及制备和应用
TWI745345B (zh) 2016-02-01 2021-11-11 瑞典商阿斯特捷利康公司 製備奧希替尼（osimertinib，azd9291）或其鹽及「azd9291苯胺」或其鹽的改良方法
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
CN117159571A (zh) 2016-02-04 2023-12-05 Sct二代有限责任公司 用于抵抗蒽环类诱导的心脏毒性的药物组合物和用途
JP6794609B2 (ja) 2016-02-04 2020-12-02 ファーマエンジン インコーポレーテッドＰｈａｒｍａｅｎｇｉｎｅ， Ｉｎｃ． チェックポイントキナーゼ１（ｃｈｋ１）阻害剤として有用な３，５−二置換ピラゾール、並びにその調製及び用途
CN105777716B (zh) 2016-02-25 2018-04-10 清华大学 一种用于靶向治疗癌症的egfr抑制剂及其制备方法与应用
CN105585557B (zh) 2016-02-25 2018-06-22 清华大学 用于靶向治疗癌症的egfr抑制剂及其制备方法与应用
CA3023176A1 (en) 2016-05-26 2017-11-30 Zeno Royalties & Milestones, LLC Egfr inhibitor compounds
CN105886648A (zh) 2016-06-06 2016-08-24 武汉海吉力生物科技有限公司 用于检测egfr基因t790m突变的试剂盒
CN106366022B (zh) 2016-08-19 2018-03-13 上海工程技术大学 一种用于制备azd9291的中间体及其制备方法和应用
CN106366072B (zh) 2016-08-19 2018-12-07 上海工程技术大学 一种azd9291的制备方法
CN106397407B (zh) 2016-08-31 2018-09-04 浙江科聚化工有限公司 抗肿瘤药物azd9291衍生物的制备方法
CN106432231B (zh) 2016-09-09 2018-06-12 无锡佰翱得生物科学有限公司 Azd9291的药用盐、及其晶型和制备方法
CN106565522A (zh) 2016-09-29 2017-04-19 福格森（武汉）生物科技股份有限公司 一种由氟代芳香化合物制备烷氧基芳香化合物的方法
CN106496196B (zh) 2016-10-20 2019-07-02 南京雷科星生物技术有限公司 一种喹唑啉、吡啶并嘧啶或则双并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
CN106543060B (zh) 2016-10-31 2018-11-06 湖南欧亚药业有限公司 一种奥斯替尼甲磺酸盐的制备方法
CN106668866A (zh) 2017-02-13 2017-05-17 江苏省中医药研究院 一种抗非小细胞肺癌的药物组合物及其应用
CN106883216B (zh) 2017-04-06 2020-03-13 张家港威胜生物医药有限公司 一种奥希替尼的制备方法

Also Published As

Publication number Publication date
IL263081A (en) 2018-12-31
RU2751341C2 (ru) 2021-07-13
KR20220130249A (ko) 2022-09-26
JP2019516766A (ja) 2019-06-20
CN112624954A (zh) 2021-04-09
CN109311858B (zh) 2021-12-03
TW201800384A (zh) 2018-01-01
AU2017269335B2 (en) 2021-07-01
MX2018013413A (es) 2019-06-06
AU2017269335A1 (en) 2018-12-13
CN109311858A (zh) 2019-02-05
AU2021240162A1 (en) 2021-10-28
TWI752033B (zh) 2022-01-11
IL263081B (en) 2021-04-29
SG10202102920QA (en) 2021-05-28
WO2017205459A8 (en) 2018-12-13
US11098030B2 (en) 2021-08-24
US20200181120A1 (en) 2020-06-11
US20170342055A1 (en) 2017-11-30
BR112018074232A2 (pt) 2019-03-06
MX2021007773A (es) 2021-08-05
SG11201809751XA (en) 2018-12-28
IL281537A (en) 2021-05-31
EP3464275A4 (en) 2019-10-30
KR102444835B1 (ko) 2022-09-19
US20210395230A1 (en) 2021-12-23
RU2018138584A (ru) 2020-06-26
US10513509B2 (en) 2019-12-24
NZ747854A (en) 2020-09-25
RU2018138584A3 (es) 2020-06-26
JP7030066B2 (ja) 2022-03-04
KR20190007434A (ko) 2019-01-22
CA3023176A1 (en) 2017-11-30
WO2017205459A1 (en) 2017-11-30
EP3464275A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
AR110038A1 (es) Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos
AR118312A2 (es) Pesticidas de azol bicíclico sustituido con heterociclos
AR100033A1 (es) Compuestos y composiciones para inhibir la actividad de shp2
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
AR109349A1 (es) Compuestos y usos
AR109709A1 (es) Inhibidores de la fosfatidilinositol 3-quinasa
AR112834A1 (es) Derivados de rapamicina
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR104720A1 (es) Moduladores de ccr2
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR097866A1 (es) Derivados de 4-azaindol
AR092809A1 (es) 3,5-diaminopirazol como inhibidor de quinasa
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR102544A1 (es) Compuestos derivados de dihidrohidantoína como herbicidas
AR100776A1 (es) Compuestos herbicidas
AR100694A1 (es) Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cáncer
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR088596A1 (es) Compuestos de bencilamina sustituidos
AR097756A1 (es) Derivados de fenilalanina sustituidos
AR093128A1 (es) Inhibidores de la syk
AR097754A1 (es) Derivados sustituidos de fenilalanina
AR095059A1 (es) Compuestos herbicidas
AR119728A1 (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2
AR087577A1 (es) Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparacion